A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)

  • Autoimmune Disorder
  • Inflammatory Bowel Disease (IBD)
  • Ulcerative Colitis
Please note that the recruitment status of the trial at your site may differ.
Trial Status:

Not yet recruiting

This trial runs in
Countries
Trial Identifier:

NCT06137183 2023-506655-19-00 GA44839

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.

      Genentech, Inc. Sponsor
      Phase 2 Phase
      NCT06137183,GA44839,2023-506655-19-00 Trial Identifier
      Vixarelimab, Placebo Treatments
      Ulcerative Colitis Condition
      Official Title

      A Phase II, Multicenter Induction Study With an Active Treatment Extension to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Patients With Moderate to Severe Ulcerative Colitis

      Eligibility Criteria

      All Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Diagnosis of UC for at least 3 months
      • Moderately to severely active UC, assessed by mMS
      • Inadequate response, loss of response to, or intolerance to conventional or advanced therapies for UC
      Exclusion Criteria
      • Diagnosis of Crohn's disease or indeterminate colitis
      • Suspicion of ischemic, radiation, microscopic, or infectious colitis
      • Prior colectomy
      • Prior treatment with systemic janus kinase (JAK) inhibitors

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now